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Abstract
Background: Several species-specific PCR assays, based on a variety of target genes are currently used in the
diagnosis of Mycoplasma bovis infections in cattle herds with respiratory diseases and/or mastitis. With this diversity
of methods, and the development of new methods and formats, regular performance comparisons are required to
ascertain diagnostic quality. The present study compares PCR methods that are currently used in six national
veterinary institutes across Europe. Three different sample panels were compiled and analysed to assess the
analytical specificity, analytical sensitivity and comparability of the different PCR methods. The results were also
compared, when appropriate, to those obtained through isolation by culture. The sensitivity and comparability
panels were composed of samples from bronchoalveolar fluids of veal calves, artificially contaminated or naturally
infected, and hence the comparison of the different methods included the whole workflow from DNA extraction
to PCR analysis.
Results: The participating laboratories used i) five different DNA extraction methods, ii) seven different real-time
and/or end-point PCRs targeting four different genes and iii) six different real-time PCR platforms. Only one
commercial kit was assessed; all other PCR assays were in-house tests adapted from published methods. The
analytical specificity of the different PCR methods was comparable except for one laboratory where Mycoplasma
agalactiae was tested positive. Frequently, weak-positive results with Ct values between 37 and 40 were obtained
for non-target Mycoplasma strains. The limit of detection (LOD) varied from 10 to 103 CFU/ml to 103 and 106 CFU/
ml for the real-time and end-point assays, respectively. Cultures were also shown to detect concentrations down
to 102 CFU/ml. Although Ct values showed considerable variation with naturally infected samples, both between
laboratories and tests, the final result interpretation of the samples (positive versus negative) was essentially the
same between the different laboratories.
Conclusion: With a few exceptions, all methods used routinely in the participating laboratories showed comparable
performance, which assures the quality of diagnosis, despite the multiplicity of the methods.
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Background
Bovine mycoplasmoses due to Mycoplasma (M.) bovis
occur in the majority of countries in the world and in-
fections are associated with a variety of clinical manifes-
tations [1], of which respiratory diseases in calves are the
most important in Europe [2]. M. bovis is considered to
be one of the major emerging pathogens of cattle in in-
dustrialized countries threatening livestock production
[3] and accounting for significant economic and produc-
tion losses in the beef and dairy industries [2, 4].
In the absence of effective vaccines [5, 6], the control of
M. bovis mycoplasmoses relies on good husbandry prac-
tices, early diagnosis and efficient antimicrobial treatments
[2]. Co-infections with viruses and easy-to-culture bacteria
which includes the Pasteurellaceae family and which are
frequent in bovine respiratory diseases (BRD) [7], may
complicate the diagnosis. Furthermore, asymptomatic
animals may act as reservoirs, enhancing the disease per-
sistence and spread within herds without clinical manifes-
tations [4, 8]. Hence, diagnostic tools for the detection of
M. bovis need to be rapid, sensitive and specific.
Awareness of the importance of M. bovis in BRD
has increased in the past decades although its preva-
lence might have been underestimated due to the lack
of veterinary laboratories routinely monitoring for
mycoplasmas. Serological methods, which indicates
invasive infection [2] are best used as a herd-level
disease diagnostic test, and are not ideal for disease
investigations at the animal level as misdiagnosis may
occur due to the lag period required for antibody for-
mation or, in contrast, to the high seroprevalence in
some cattle populations [9].
For direct diagnosis, conventional microbial culture of
M. bovis is laborious and time-consuming (up to 7 days)
as the bacterium has specific and demanding growth
conditions. Furthermore, with limited options for spe-
cific selection for M. bovis by cultural means, diagnosis
typically requires a post-culture identification test as
other proven pathogenic or opportunistic mycoplasmas
like M. dispar or M. bovirhinis and M. arginini, respect-
ively can be isolated from the same clinical samples [10].
Traditional biochemical or growth inhibition tests used
for species confirmation has been replaced by several
identification techniques such as sandwich ELISA [11],
dot immunobinding membrane-filtration tests (MF-dot)
[12] or more recently matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-
TOF MS) [13, 14] that demonstrate high specificity, but
do not improve the overall sensitivity of the diagnosis
since they depend on a cultivation step to isolate the
organism.
Hence, PCR-based techniques that allow rapid (i.e.
within a few hours), sensitive and specific detection have
contributed significantly to an improved diagnosis of M.
bovis. Today several highly sensitive and species-specific
PCRs targeting a variety of genes are used in the diagno-
sis of Mycoplasma-associated diseases for M. bovis in
cattle herds with BRD and/or mastitis (see review by
Parker et al., [15] and Table 1 for an overview). However,
few studies are dedicated to the comparison of overall
performance of these assays [16]. This study describes
the comparison of several PCR methods currently used
in six national veterinary institutes across Europe. Three
different sample panels were collated and used to assess
the analytical specificity, analytical sensitivity and com-
parability of the different PCR methods, respectively. Re-
sults were also compared, when appropriate, to those
obtained through culturing. The sensitivity and compar-
ability panels were based on bronchoalveolar fluids
(BALFs), artificially contaminated or naturally infected,
and hence the comparison of the different methods in-
cluded the whole workflow from DNA extraction to
PCR analysis.
Materials
Mycoplasma isolates, growth conditions and viability
controls
The mycoplasma isolates used in the study are listed in
Table 2. Isolates were grown in PPLO broth, modified as
previously described [17], at 37 °C in 5% CO2, except for
M. dispar and U. diversum which were grown in modi-
fied Friis medium and Eatons general purpose growth
medium, respectively [18]. The length of culture was
adapted for each species from 3 to 5 days to reach early
stationary phase. To enumerate the M. bovis culture
used for the analytical sensitivity assay (see hereafter),
the number of colony forming units (CFU) per ml was
determined by plating spots of 2 μl of serial 10 fold broth
dilutions onto PPLO agar plates. After incubation for 5
days, colonies from nonconfluent spots were counted
under a stereomicroscope and the mean final cell con-
centration was determined.
For viability control of M. bovis in the BALF samples,
laboratories (Lab) 1 and 4 performed a bacteriological
examination for M. bovis using different methods. In
Lab 1, PPLO agar plates were flooded with 200 μl of
each BALF (dilution series for sensitivity and individual
BALF for comparability), the excess of culture was
removed by pipetting and after 5 days incubation the
colonies were observed under a stereomicroscope. If col-
onies of typical mycoplasma morphology were observed,
they were picked and grown in PPLO broth until turbid-
ity was observed. In parallel direct 10 fold dilution series
up to 10− 5 of BALF in PPLO were prepared and incu-
bated until turbidity. Turbid broths (from picked col-
onies or dilution series) were analysed for the presence
of M. bovis or other mycoplasma species using MF-dot
tests [12] and/or real time PCR (MPBO50). In Lab 4,
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BALF samples were cultured directly on Friis medium
plates and also one 10 fold dilution was made from the
BALF in Friis broth [19]. Plates were incubated for 7
days at 37 °C in 5% CO2, and inspected every second day
under the microscope for mycoplasma growth. Broth
medium was incubated at 37 °C for 3 days. The growth
and color change were monitored every other day. All
broth cultures were examined for presence of M. bovis
by oppD real-time PCR and suspected samples were sub-
cultured on Friis medium plates as described above. The
results of the oppD real-time PCR on broth were com-
pared with the results of this PCR assay directly on
BALF samples and if there was an increase of Ct values
it was concluded that this increase was due to
Table 1 Overview of PCR methods in literature for detection of M. bovis
Method Characteristics Targeted gene Published by
End-point PCR For detection of M. bovis in milk samples and nasal swabs oppD/F [36]
For detection of M. bovis and M. agalactiae in diagnostic samples uvrC [26]
Design of a species-specific PCR assay for the identification and differentiation of
M. agalactiae and M. bovis
polC [25]
Development of a M. bovis species-specific PCR assay. Vsp [37]
PCR-DGGE PCR followed by denaturing gradient gel electrophoresis (DGGE) fingerprinting.
For the simultaneous detection of mixed mycoplasma populations including
M. bovis.
16S rRNA [27, 35, 38]
DNA microarray For parallel detection of 37 Mycoplasma species, including M. bovis. 23S rRNA; tuf [39]
Real-time PCR For quantifying the load of M. bovis in milk, nasal and conjunctival samples from cattle. oppD [23]
For pathogens associated with BRD, including M. bovis. oppD [40]
For detection of M. bovis in diagnostic samples. uvrC [24, 41, 42]
For detection of M. bovis in bovine milk samples fusA [43]
For detection of M. bovis in bovine milk and lung samples. 16S rRNA [44]
For detection of M. bovis, M. dispar and M. bovirhinis in bronchoalveolar lavage fluid
from calves.
16S rRNA [22]
Table 2 Identity of 17 Mycoplasma strains used in the ring trial to test for the analytical specificity of M. bovis PCR methods
Strain Number Strain collection Source Country Origin (sample, year)
Mycoplasma bovis F8065 Anses [45] France Bovine respiratory disease, 2014
Mycoplasma bovis F8127 Anses [45] France Bovine respiratory disease, 2013
Mycoplasma bovis F8428 Anses [45] France Bovine respiratory disease, 2013
Mycoplasma bovis F8619 Anses [45] France Bovine respiratory disease, 2014
Mycoplasma bovis L11480 Anses [45] France Bovine respiratory disease, 2000
Mycoplasma bovis L15711 Anses [45] France Bovine respiratory disease, 2011
Mycoplasma bovis L8905 Anses [45] France Bovine respiratory disease, 1995
Acholeplasma laidlawii PG8 NCTC 10116
or ATCC 23206
Anses TS UK Sewage, 1936
Mycoplasma agalactiae 5632 Anses [46] Spain Caprine, joint, 1991
Mycoplasma alkalescens PG51 NCTC 10135
or ATCC 29103
Anses TS UK Bovine nasal cavity
Mycoplasma arginini F9238 Anses Field strain (unpublished) France Respiratory disease, caprine, 2014
Mycoplasma bovigenitalium PG11 NCTC 10122
or ATCC 19852
Anses TS Not known Bovine genital tract
Mycoplasma bovirhinis F11020 Anses Field strain (unpublished) France Bovine respiratory disease, 2016
Mycoplasma canadense 275C Anses TS Canada Prepuce of a bull
Mycoplasma canis PG14– NCTC 10146
or ATCC 19525
Anses TS UK Dog throat
Mycoplasma dispar NCTC 10125 APHA TS UK Pneumonic calf lung
Ureaplasma diversum 382B16 APHA Field strain (unpublished) UK Bovine, swab from unspecified site
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multiplication of viable M. bovis organisms. A BALF was
considered as culture positive when at least one of the
different methods returned a positive result.
Sample panels
Three different sample panels (I, II and III) were com-
piled to assess the analytical specificity, analytical sensi-
tivity and comparability of the different M. bovis PCR
methods, respectively (see hereafter for details of the
sample panels).
Sample panel I: Analytical specificity on DNAs of
mycoplasma strains
The analytical specificity was defined as the ability of the
assay to distinguish target from non-target organisms
[20]. The inclusion list comprises seven M. bovis isolates
belonging to different subtypes that used to circulate or
are currently circulating in France and other countries
[21], while the exclusion list was composed of ten strains
belonging to ten non-target mycoplasma species that
can be recovered from BRD clinical samples (9/10) or
are genetically close to M. bovis (1/10, M. agalactiae)
(Table 2). For each strain, a 20 ml broth culture was
grown at 37 °C up to the stationary phase and myco-
plasma cells were harvested by a 30 min centrifugation
at 9000 g and 4 °C. DNA was extracted from pelleted
cells either using 3 DNeasy Mini Spin Columns from the
DNeasy 96 Blood & Tissue Kit (Qiagen) or the Maxwell®
16 Tissue DNA purification kit (Promega). Each DNA
solution was diluted to a 10 ng/μl concentration, ali-
quoted into anonymized individual tubes (marked from
A to Q) for each laboratory and frozen at − 80 °C.
Sample panel II: Analytical sensitivity on BALF spiked with
M. bovis
The analytical sensitivity of the M. bovis PCR assays was
defined as the ability of the assay to detect the lowest
concentration of M. bovis in CFU/ml in BALF [20]. A
pool of BALFs sampled from specific pathogen free
(SPF) calves of 3 weeks old was spiked using an enumer-
ated culture of strain 147,826–1 (VB) (isolated in South
of Sweden in 2016 from mastitis milk) in order to get a
final 1 × 108 CFU/ml concentration. Ten-fold serial dilu-
tions (n = 7) of this mixture were prepared in BALF
resulting in a range from 1 × 107 to 1 × 101M. bovis
CFU/ml. All dilutions were performed in the same BALF
pool, aliquoted afterwards in separate anonymized sam-
ples (marked from 1 to 7) for every laboratory and fro-
zen at − 80 °C.
Sample panel III: Comparability on BALF samples from the
field
For comparison of the results of the PCR methods on
field samples, BALF samples (n = 21) were selected from
a set of BALF from veal calves, sampled between
October 2013 and April 2014 and used for the evalu-
ation of a triplex real-time PCR for the detection of M.
bovis, M. dispar and M. bovirhinis in BALF [22] and
stored since then at − 80 °C. In that study, BALF samples
were tested from calves on farms with BRD and were
positive for M. bovis with Ct values below 30 (in this
work BALFs n° 4, 6, 8, 9, 13, 16 and 20), weak-positive
with Ct values between 30 and 40 (in this work BALFs n
° 1, 3, 14, 15, 18, 19 and 21) or negative with Ct values
above 40 (in this work BALFs n° 2, 5, 7, 10, 11, 12, 17).
These 21 BALFs were anonymised, aliquoted and sent to
each participating laboratory on dry ice. Two laborator-
ies performed bacteriological examination of the BALF
samples as described above.
Participating institutes
Six institutes for Animal Health in six different Euro-
pean countries participated in the M. bovis PCR ring
trial: the Animal and Plant Health Agency (APHA), UK;
the National Veterinary Institute, Technical University
of Denmark (DTU), Denmark; the Finnish Food Safety
Authority (Evira), Finland; the French Agency for Food,
Environmental and Occupational Health & Safety
(ANSES), France; the National Veterinary Institute
(SVA), Sweden and the Wageningen Bioveterinary Re-
search (WBVR), The Netherlands. The institutes were
anonymously listed as laboratories 1 to 6.
Distribution of samples and ring trial procedures
Samples were randomised and sent anonymized on dry
ice to all participating laboratories, which were asked to
i) note the date of reception, ii) confirm that samples
were still frozen at reception and iii) store the samples
at − 80 °C until analysis. A report form was prepared and
every laboratory was asked to report results in terms of
positive, negative or doubtful for M. bovis or, in case of
problems with the validation of negative and positive
controls, as a run failure. Users of end-point PCR were
asked to report the electrophoresis technique used and
the quantity of PCR mix loaded. Users of quantitative
tests were asked to report the Ct values and also the Ct
value of the internal positive control (IPC) of the test.
All laboratories were asked to document the platform on
which the PCR method was run.
For analysis of samples of panel I, every laboratory was
asked to i) defrost the aliquots at room temperature (not
longer than 30 min), ii) make a 1/10 dilution of each
DNA sample (to be stored at 4 °C before running PCR
test), iii) run a PCR on the original DNA sample and on
the 1/10 DNA dilutions in duplicate using 5 μl of each
DNA sample in the PCR mix. All these analyses had to
be performed on the day when samples were defrosted
and in the same run.
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For analysis of samples of panel II and III every labora-
tory was asked to i) extract DNA from 200 μl BALF of
the entire dilution series of spiked samples (panel II) and
from the field samples (panel III) using the method rou-
tinely performed in their laboratory, ii) resuspend the
DNA in an equal 200 μl volume, iii) use 5 μl of the DNA
in their PCR mix and iv) run the PCR test in duplicate.
Methods used in the laboratory
Five different DNA extraction methods were used by the
laboratories participating in the ring trial (Table 3). Labs
1, 3 and 4 used the same technique (spin column,
silica-membrane extraction from Qiagen). The other
three laboratories (2, 5 and 6) all used a robot with
magnetic-particle technology. However the kits and the
type of robots varied (Table 3).
Seven different PCR methods were used by the partici-
pating laboratories (Table 3). Labs 1, 2 and 4 used the
commercial real-time MPBO50 kit from ThermoFisher
Scientific which is based on the polC gene. Labs 3, 4 and 5
used PCRs based on the detection of the oppD gene [23].
However the chemistry and / or real-time PCR kits dif-
fered (Table 3). Lab 4 used a real-time PCR based on de-
tection of the uvrC gene [24] and Lab 6 used a real-time
PCR based on the V3-V4 16S rRNA gene [22]. For ampli-
fication, six different real-time PCR platforms were used
(LightCycler 480, Stratagene MX3000, Rotor-Gene,
Bio-Rad CFX96, ABI 7500 and ABI 7500 Fast).
In addition to real-time PCRs, end-point PCRs (n = 2)
were also run. Lab 1 used a PCR method based on polC
[25] whereas Lab 2 used uvrC [26] for detection of M.
bovis and a PCR-DGGE method based on the 16S rRNA
gene [27], without primary culture step.
Statistical analysis
The linear correlation coefficient (r), the slope and the
amplification efficiency (E) of the PCR methods were
calculated between the Ct values obtained in the
real-time PCRs and the number of M. bovis CFU/ml
[28]. Calculations were performed using Microsoft Excel
spreadsheets.
Results
Analytical specificity using DNAs of mycoplasma strains
(sample panel I)
The analytical specificity of the PCR methods was
evaluated using DNAs of a panel of target and
non-target Mycoplasma isolates (sample panel I; n =
17). All real-time PCR tests were positive using M.
bovis DNA extracts except for one test, which was
obviously due to an experimental failure (from lab 3)
(Fig. 1). Negative PCR results were obtained with the
non-M. bovis DNAs, except for the 16S PCR by lab 6
which showed a clear positive result on M. agalactiae
(Fig. 1). Furthermore, several real-time PCR tests of
DNA samples from which M. bovis was expected to
be absent showed weak positive results with Ct values
greater than or equal to 37 (Fig. 1). This was espe-
cially valid for samples with 50 ng of DNA in the
PCR mix, i.e. 5 μl of 10 ng/μl solution. Hence, with
most of the PCR assays, Ct ≥ 37 were further regarded
as doubtful.
Results from end-point PCRs were in agreement with
those of real-time PCRs except for the uvrC PCR using
1/10 diluted DNA of M. bovis that was poorly reprodu-
cible giving alternatively positive or negative results
(Fig. 1). The PCR-DGGE analysis fully confirmed the
identification of the DNA samples.
Analytical sensitivity on BALF spiked with M. bovis
(sample panel II)
The analytical sensitivity of the M. bovis PCR methods
was determined on ten-fold serial dilutions of a pool of
BALFs from SPF calves, spiked with M. bovis (Sample
panel II; Fig. 2). A high linear correlation (r > 0.97) be-
tween the Ct values and the number of CFU/ml was
found for all assays. The slopes ranged from − 2.5 (Lab
1) to − 3.4 (Lab 5) which corresponds to an efficiency
(E) of 166 and 97% respectively (Fig. 2).
The limit of detection (LOD) expressed in CFU/ml
in the BALF pool varied from 10 to 103 between the
different real-time PCR assays. This variation was ob-
served even between laboratories using the same PCR
kit (MPBO50, used in Lab 1, 2 and 4) and the same
DNA extraction kit (Qiagen, silica-membrane, Lab 1
and 4), suggesting an impact of the PCR platform
(LightCycler 480 in Lab 1 versus Bio-rad CFX96 in
Lab 4). Similarly, in the PCR method based on the
oppD gene the LOD was 102 (Labs 3 & 4) and 103
CFU/ml (Lab 5) using different types of DNA extrac-
tion methods (Labs 3 &4: spin column; Lab 5:
magnetic-particle technology). Detection based on the
16S rRNA gene resulted in a low LOD due to the du-
plicate copies of the target in the genome (Lab 6). In
Lab 4, three different techniques were used on the
same extracted DNA batches which allows a classifi-
cation of the real-time PCR methods as a function of
their respective sensitivity, i.e. uvrC > oppD > polC.
The LOD of the end-point PCRs was comparable to
that of real-time PCR when targeting the polC gene (102
CFU/ml, Lab1) but was higher when targeting the uvrC
gene (106 CFU/ml, Lab 2) or performing the PCR-DGGE
method (105 CFU/ml, Lab 2).
The culture methods used for viability control of M.
bovis in the BALF samples seemed to be very sensitive
since for both laboratories (Lab 1 & Lab 4) the LOD was
102 CFU/ml of BALF.
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Comparability on BALF samples from the field (sample
panel III)
A set of 21 BALFs from calves originating from herds
with BRD were analysed by PCR in the six laboratories
and by culture methods in Lab 1 and 4. Figure 3 shows
the mean Ct values (two repeats) obtained by each la-
boratory. For each BALF, the median dispersion of the
mean Ct values was 3.5 but differences reached up to 6.6
Ct values at the maximum. For instance, BALF n°1 had
a mean Ct value of 37.1 in the hands of Lab 1 but 30.5
in the hands of Lab 6 (Fig. 3).
Of the seven BALF samples considered as negative (by
culture but also by considering previous results from Cor-
nelissen et al. [22], i.e. BALFs n° 2, 5, 7, 10, 11, 12, 17; Fig. 3),
none were detected with a Ct < 37. In contrast, of the 14
BALFs that were culture-positive, 11 (79%) were detected
by all laboratories with Ct < 37, whereas three (n° 14, 15
and 21; Fig. 3) were weak-positive, doubtful (Ct = 37) or
negative at the different laboratories (Fig. 3).
The polC-end point PCR gave coherent results com-
pared to the real-time PCR assays in 86% (12/14)
culture-positive BALFs but failed to detect BALF n° 15
Fig. 1 Determination of the analytical specificity of various M. bovis PCR assays in use by six laboratories (Lab 1 to Lab 6) on DNA from a panel of
seven M. bovis strains and 10 non-target mycoplasma species. DNA of each strain was tested in two concentrations: once with 5 μl of 10 ng/μl
(pure) and twice with 5 μl of a 1/10 dilution (1:10), except for Lab 4 that used 1 μl of DNA only. Raw data to this figure are provided in Additional file 1
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Fig. 2 (See legend on next page.)
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and 21. In contrast, the uvrC end-point PCR and the
PCR-DGGE analysis yielded 64% (9/14) and 50% (7/14)
false negative results, although the latter test was able to
identify also M. dispar and M. bovirhinis DNA from
these samples.
Discussion
Six laboratories participated in the ring trial and a total
of five different DNA extraction methods, seven differ-
ent real-time and/or end-point PCR methods targeting
four different genes and six different real-time PCR
platforms were used (Table 2). Among the tested PCR
assays there was one ready-to-use commercial kit
(MPBO kit, ThermoFisher Scientific); the others were
in-house, validated, PCR assays.
Differences in analytical specificity and analytical sen-
sitivity were observed between the various real-time
PCR methods. A clear cross reaction was observed in
the real-time PCR method of Lab 6 with M. agalactiae,
which is genetically close to M. bovis with a 99% nucleo-
tide similarity between their 16S rRNA sequences [29]
but usually not isolated from the bovine host with a few
(See figure on previous page.)
Fig. 2 Determination of the analytical sensitivity of various M. bovis PCR assays in use by six laboratories (Lab 1 to Lab 6) on spiked bronchoalveolar
lavage fluid (BALF) samples. Ten-fold serial dilutions (n = 7) of a mixture of 1 × 108M. bovis CFU/ml were prepared in BALF resulting in a range of 1 ×
107 to 1 × 101M. bovis CFU/ml and tested by the various PCR methods. Viability of M. bovis in the BALF samples was verified with culture. Raw data to
this figure are provided in Additional file 1
Fig. 3 Comparability of results of various PCR methods in use by six laboratories (Lab 1 to Lab 6) on bronchoalveolar lavage fluid (BALF) samples
(n = 21) from veal calves from farms with bovine respiratory disease (BRD). BALF samples were tested twice by the PCR methods and the mean
Ct values were calculated from the real-time PCRs. Viability of M. bovis in the BALF samples was verified with culture. On the basis of the culture
results, the figure was split in two parts, either with BALF samples negative or positive for M. bovis by culture. Raw data to this figure are provided
in Additional file 1
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exceptions [30]. Moreover, weak positive results with Ct
values between 37 and 40 were obtained on non-target
Mycoplasma strains which could result in misinterpret-
ation of results and highlights the requirement for
thorough assessment of cut-off during validation at indi-
vidual laboratory level. Differences in the analytical sen-
sitivity appeared to be 10–100 fold between the different
real-time PCR methods. Furthermore, in the compar-
ability assay differences in mean Ct values between la-
boratories appeared to be 6.6 Ct values at the maximum,
the median was 3.5 Ct values. A difference of 3.3 Ct
values is equal to a 10 fold difference and differences be-
tween the real-time PCR methods were therefore 10 to
100 fold, which is comparable to the difference in analyt-
ical sensitivity. Nevertheless, this difference did not im-
pact on the qualification of the BALF samples (i.e.
positive versus negative), with a few exceptions (Fig. 3).
Apparently different real-time PCR methods with a vary-
ing sensitivity can be used for the diagnosis of M. bovis
in clinical BALF samples.
For the present ring trial, BALF from veal calves was
selected as a representative clinical sample to compare
the efficiency of PCR diagnosis of M. bovis. It is esti-
mated that M. bovis is a contributing factor in at least
25% of cases of BRD in calves and that BALFs are valu-
able samples for detection of M. bovis in cases of BRD
in calves [2, 3, 21, 31]. Other possible samples from BRD
cases could include lung tissue samples or swabs from
the respiratory tract. However, these would have been
less suitable than BALF for homogenous aliquoting and
distribution to participating laboratories. Our results
should not be generalized to other types of samples, like
semen, or milk, or joint fluid/swabs that are increasingly
being used for the diagnosis of M. bovis [1, 4, 32]. Ring
trials based on these types of sample materials warrant
further investigation.
The variety of methods in this study is consistent
with the number of PCRs described in literature for
M. bovis detection (Table 1). In order to take into ac-
count the specific know-how of each participating la-
boratory, no technique was imposed upon the
laboratories in the design of our ring trial. This is be-
cause the focus of the study was to compare the vari-
ous tests as normally used as evaluated by each
laboratory for routine testing. The main consequence
of this choice was that the statistical analysis per-
formed in this study was essentially descriptive, with
more detailed statistical analysis of the results consid-
ered beyond the scope of the present study. While,
differences in protocols (such as the number of amp-
lification cycles, the volume of DNA in the mix, etc.)
may in part explain the differences in overall perfor-
mances of the methods, it was not the aim of the
paper to analyse these in detail.
In the present ring trial, the detection of M. bovis by
culture from naturally or artificially contaminated
BALFs, as conducted by two laboratories, showed a sen-
sitivity comparable or even better than that of real-time
PCR assays. This is in agreement with a previous study
that showed no significant difference in the proportion
of culture and PCR positive samples [33]. However the
authors also stated that the best method to detect and
identify M. bovis was also dependent on the sample type.
Here, the naturally infected BALFs contained several
other bacteria [34] including mycoplasmas [22] among
which M. bovirhinis, which is a known fast grower.
Hence, M. bovirhinis present in the sample could over-
grow M. bovis and lead to false negative results depend-
ing on the techniques used afterwards to differentiate M.
bovis from M. bovirhinis. The choice of the most accept-
able culture medium is also critical and hence diagnosis
by culture needs far more expertise than is required to
perform PCR, although the latter necessitates good qual-
ity DNA and a reliable PCR assay. Of the PCR-based
tests investigated in this study only the triplex real-time
PCR used by Lab 6 and the PCR-DGGE method used by
Lab 2 are able to offer simultaneous identification of
three [22] or more Mycoplasma species, including hardly
cultivable or non-cultivable ones from clinical samples
[35]. It should also be noted that PCR-DGGE is most
routinely applied in the diagnostic laboratory setting fol-
lowing an initial culture step for clinical sample diagnos-
tics which was not performed here. In the end, the
choice of the most suitable method for M. bovis diagno-
sis must reflect the veterinary requirements for a robust
and reproducible approach to testing.
Conclusion
In this study the performance of PCR methods in use by
six Animal Health laboratories across six European
countries was compared in a ring trial. The analytical
specificity of the PCR methods was comparable except
for M. agalactiae, which was tested positive by Lab 6 be-
cause of the use of 16S rRNA as the target gene. The
LOD of the real-time PCR methods varied from 10 to
103 CFU/ml and differences in sensitivity to the same
order of magnitude were found in the real-time PCR as-
says on BALF samples of naturally infected veal calves.
Despite these differences, and with the exception of the
end-point PCR on the uvrC gene and the PCR-DGGE
method, highly comparable PCR results were obtained
on BALF samples from naturally infected veal calves
leading to the conclusion that several DNA isolation and
PCR methods can give consistent diagnostic test results.
Culture results confirmed the presence of viable M.
bovis in the tested BALF samples, and also confirmed
the diagnostic test results of the M. bovis PCR methods
on these samples.
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Additional file
Additional file 1: Raw data to Figs. 1, 2 and 3 are provided in
Additional file 1. (XLSX 29 kb)
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